Pre-treatment circulating regulatory T cell count analysis of advanced cervical squamous cell carcinoma patients

郑雨薇; 黄啸; 郭林

doi:10.3969/j.issn.1007-3969.2015.04.001

您当前的位置：

首页 >

文章列表页 >

Pre-treatment circulating regulatory T cell count analysis of advanced cervical squamous cell carcinoma patients

更新时间：2025-12-31

- Pre-treatment circulating regulatory T cell count analysis of advanced cervical squamous cell carcinoma patients
- China Oncology Vol. 25, Issue 4, Pages: 241-246(2015)
- 作者机构：
  
  1. 复旦大学附属肿瘤医院病理科，复旦大学上海医学院肿瘤学系,上海,200032
  2. 复旦大学附属肿瘤医院妇瘤科，复旦大学上海医学院肿瘤学系,上海,200032
  3. 复旦大学附属肿瘤医院检验科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2015.04.001
  CLC：
- Published Online：25 May 2015，
  
  Published：25 May 2015
- 稿件说明：
移动端阅览
郑雨薇,黄啸,郭林,等. 中晚期宫颈鳞癌患者治疗前外周血Treg计数分析[J]. 中国癌症杂志, 2015, 25(4): 241-246.

郑雨薇, 黄啸, 郭林. Pre-treatment circulating regulatory T cell count analysis of advanced cervical squamous cell carcinoma patients[J]. China Oncology, 2015, 25(4): 241-246.
郑雨薇,黄啸,郭林,等. 中晚期宫颈鳞癌患者治疗前外周血Treg计数分析[J]. 中国癌症杂志, 2015, 25(4): 241-246. DOI： 10.3969/j.issn.1007-3969.2015.04.001.

郑雨薇, 黄啸, 郭林. Pre-treatment circulating regulatory T cell count analysis of advanced cervical squamous cell carcinoma patients[J]. China Oncology, 2015, 25(4): 241-246. DOI： 10.3969/j.issn.1007-3969.2015.04.001.

摘要

背景与目的：中晚期宫颈鳞癌同期放化疗(concurrent chemoradiotherapy，CCRT)治疗前性价比高的疗效判断方法较有限，该研究拟通过检测治疗前外周血CD4

CD25

CD127

Low/-

调节性T细胞(regulatory T cells，Tregs)亚群计数及血清鳞癌抗原(squamous cell carcinoma antigen，SCC-Ag)水平，评价两者预测临床疗效的可行性。方法：采集44例Ⅱ

~Ⅳ

期宫颈鳞癌患者行CCRT治疗前的外周血标本，分别利用流式细胞免疫表型分析和酶联免疫法检测外周血CD4

CD25

CD127

Low/-

Treg计数及血清SCC-Ag水平。收集临床和病理资料，并统计检验2个指标对疗效的预测作用。结果：治疗前外周血CD4

CD25

CD127

Low/-

Treg计数在临床有效组低于无效组［(8.78±2.80)% vs (10.95±2.56)%，P0.05］，血清SCC-Ag在不同临床疗效组间差异无统计学意义，且这2个、指标之间未发现相关性(Spearman’rho=-0.093，P=0.540)。经受试者工作特征(receiver operating characteristic，ROC)曲线确定治疗前外周血CD4

CD25

CD127

Low/-

Treg及血清SCC-Ag最佳界值分别为9.76%与9.50 ng/mL。单因素分析显示，治疗前外周血CD4

CD25

CD127

Low/-

Treg计数(OR=1.901，95%CI：1.112~3.219，P=0.017)对CCRT疗效有预测作用，而血清SCC-Ag水平无预测作用(OR=0.998，95%CI：0.001~4.253，P=0.897)。多因素Logistic回归分析显示，治疗前外周血CD4

CD25

CD127

Low/-

Treg为独立的临床疗效预测因子(OR=3.115，95%CI：1.253~7.742，P=0.014)。结论：治疗前外周血CD4

CD25

CD127

Low/-

Treg计数用于中晚期宫颈鳞癌患者CCRT临床疗效预测具有可行性。

Abstract

Background and purpose: Due to the lack of cos

t-effective pre-treatment predictors for advanced cervical squamous cell carcinomas treated with concurrent chemoradiotherapy (CCRT)

both baseline circulating CD4

CD25

CD127

Low/-

regulatory T cell (Treg) count and serum squamous cell carcinoma antigen (SCC-Ag) level were measured for this feasibility study. Methods: Peripheral blood samples were collected from 44 patients with stage Ⅱ

-Ⅳ

cervical squamous carcinomas before CCRT. Flow cytometry immunophenotyping and enzyme-linked immunosorbent assay were used for circulating CD4

CD25

CD127

Low/-

Treg count and serum SCC-Ag level testing

respectively. Clinical and pathological characteristics were retrospectively reviewed to analyze the predictive value of the 2 indexes. Results: The baseline circulating CD4

CD25

CD127

Low/-

Treg count was lower in the patient group with positive treatment response than in the group with negative response ［(8.78±2.80)% vs (10.95±2.56)%

P0.05］

and the serum SCC-Ag level showed no significant difference between the 2 groups. No correlation was detected between these 2 markers (Spearman’rho=-0.093

P=0.540). Determined by plotting receiver operating characteristic curves

the best cut-off points were 9.76% for circulating CD4

CD25

CD127

Low/-

Treg count and 9.50 ng/mL for serum SCCAg level

respectively. Univariate analysis showed that pretherapeutic circulating CD4

CD25

CD127

Low/-

Treg count (OR=1.901

95%CI: 1.112-3.219

P=0.017)

but not serum SCC-Ag level (OR=0.998

95%CI: 0.001-4.253

P=0.897)

was predictive of clinical response to CCRT. Multivariate Logistic regression analysis revealed that pre-treatment CD4

CD25

CD127

Low/-

Treg count was an independent predictor for clinical response to CCRT (OR=3.115

95%CI: 1.253-7.742

P=0.014). Conclusion: Pretherapeutic circulating CD4

CD25

CD127

Low/-

Treg count is a feasible method to predict clinical response to CCRT in patients with advanced cervical squamous cell carcinomas.

关键词

Keywords

references

Views

1658

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of oral nutritional supplements on nutritional status and quality of life in patients with nasopharyngeal carcinoma receiving chemoradiotherapy

Clinical observation of TPF induction chemotherapy versus PF induction chemotherapy combined with concurrent chemoradiotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma

The progress of targeted therapy in locally advanced head and neck squamous cell carcinomas

Related Author

丁慧萍

窦圣金

汪　琼

马雄辉

梁彩霞

江丹贤

郭晔

Related Institution

复旦大学附属肿瘤医院营养科，复旦大学上海医学院肿瘤学系

上海交通大学医学院附属第九人民医院放疗科

广东医学院附属医院肿瘤科

复旦大学附属肿瘤医院肿瘤内科，复旦大学上海医学院肿瘤学系

AI问答

⁰